Farmak International Gains Key UK Authorizations: MIA & WDA(H) Secured
Farmak International UK, (legally represented by Farmak Pharmaceuticals UK Ltd), a subsidiary of Farmak Group, has achieved a significant milestone.
We have obtained the Manufacturer’s/Importation Authorisation (MIA) and Wholesale Distribution Authorisation (WDA(H)), as well as the accompanying GMP (Good Manufacturing Practice) and GDP (Good Distribution Practice) certificates. This accomplishment follows an inspection by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), which reported with no critical or major observations.
With these newly granted authorizations, Farmak International UK can:
– Import medicines from outside the European Union and act as a batch release site.
– Procure, hold, supply, or export medicinal products sourced in the UK or imported from approved countries
This development positions Farmak International’s UK operations as independent and fully licensed within one of the world’s most highly regulated pharmaceutical markets, eliminating the need for third-party marketing authorization holders. It marks a transformative step in the company’s journey to strengthen and broaden its international footprint.
Achieving these licenses is a major accomplishment, reinforcing Farmak International’s commitment to high standards and responsible growth. Huge congratulations to our UK team for their hard work and dedication in making this possible!
Viktor Kostiuk CEO, Farmak International
This milestone positions us as a fully independent player in the UK pharmaceutical market, and we are incredibly proud of what we have achieved.
Marc Hourigan Head of UK & Republic of Ireland, Farmak International
A Steady Path to Success in the UK
Farmak International’s success in the UK has been built on carefully planned strategic steps over the past few years:
• 2025 – MIA & WDA(H) awarded following an MHRA inspection
with no critical or major observations.
• September 2024 – Acquisition of A&S Pharma Holdings Ltd,
boosting infrastructure and capabilities in the UK.
• Early 2024 – Established a dedicated Farmak International
office in the UK, enhancing local operations and market outreach.
• 2024 – Registration of new medicinal products, including an
advanced anesthetic, to expand the company’s offering in the UK market.
Collectively, these milestones reflect Farmak International’s unwavering commitment to delivering high-quality, innovative healthcare solutions worldwide.
About Farmak Group, Farmak International and Farmak Pharmaceuticals UK Ltd
Farmak Group is a global pharmaceutical business tracing its roots to Ukraine since 1925, with production facilities in two countries in Europe, and 13 companies and international offices in Poland, the Czech Republic, Slovakia, the United Kingdom, the UAE, Vietnam, Switzerland, Kazakhstan, Uzbekistan, Kyrgyzstan, Mongolia, Moldova, Spain, and Ukraine. The products of Farmak Group are exported to 60 countries worldwide, spanning key regions including Europe, Asia, the Middle East and Africa (MEA), and Latin America.
Farmak International, headquartered in Switzerland, is responsible for Farmak Group’s global business operations, asset management, and international market expansion. Farmak International includes entities established in Switzerland, Spain, Poland, the Czech Republic, Slovakia, the United Kingdom, the UAE, and Vietnam.
Farmak Pharmaceuticals UK Ltd serves as a key regional hub for expanding market presence, facilitating partnerships, and delivering high-quality pharmaceutical products across the UK and the Republic of Ireland.
